[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053350":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":81,"collaborators":41,"id":83,"slug":41,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":41,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":41,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":106,"overallStatus":109,"whyStopped":41,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8,15,19,23,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Acute lung injury","OTHER","Acute lung injury undergoing FAPI\u002FPET\u002FCT",[13,14],"Drug: [18F]FAPI-74","Diagnostic Test: 18F-FAPI-74 PET\u002FCT Imaging",{"label":16,"type":10,"description":17,"interventionNames":18},"Allogeneic stem cell transplantation","Allogeneic stem cell transplantation undergoing FAPI\u002FPET\u002FCT",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Cardiovascular diseases","Cardiovascular diseases undergoing FAPI\u002FPET\u002FCT",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Interstitial lung disease","Interstitial lung disease undergoing FAPI\u002FPET\u002FCT",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"Lung allograft transplantation","Lung allograft transplantation undergoing FAPI\u002FPET\u002FCT",[13,14],{"label":32,"type":10,"description":33,"interventionNames":34},"Pulmonary arterial hypertension","Pulmonary arterial hypertension undergoing FAPI\u002FPET\u002FCT",[13,14],[36,42],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","[18F]FAPI-74","Participants will undergo baseline diagnostic 18F-FAPI-74 PET\u002FCT in addition to standard of care imaging (non-contrast chest CT and 18FFDG- PET\u002FCT, cardiac MRI for heart cohort). A follow-up 18F-FAPI- 74 PET\u002FCT with SOC imaging will be performed at 8 to 12 months after the initial scan to assess progression and or the effects of therapies.",[9,16,20,24,28,32],null,{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":41},"DIAGNOSTIC_TEST","18F-FAPI-74 PET\u002FCT Imaging","Fibroblast activation protein-targeted PET detects activated fibroblasts in a range of inflammatory and fibrosing cardiovascular and pulmonary disorders. It is a sensitive and quantifiable intervention to diagnose and monitor the natural history of cardiopulmonary disorders and\u002For the effects of antifibrotic interventions.",[9,16,20,24,28,32],[48],{"name":49,"affiliation":50,"role":51},"Anthony F Suffredini, M.D.","National Heart, Lung, and Blood Institute (NHLBI)","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":41,"email":57},"Gloria Y Pastor, C.R.N.P.","CONTACT","(301) 402-3484","pastorg@cc.nih.gov",{"name":49,"role":55,"phone":59,"phoneExt":41,"email":60},"(301) 496-9320","asuffredini@mail.nih.gov",[62],{"facility":63,"status":41,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"National Institutes of Health Clinical Center","Bethesda","Maryland","20892","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-77.10026,38.98067,{"lat":73,"lon":72},[76],{"name":77,"role":55,"phone":78,"phoneExt":79,"email":80},"NIH Clinical Center Office of Patient Recruitment (OPR)","800-411-1222","TTY dial 711","ccopr@nih.gov",{"type":82,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100053350",false,"NCT07613099","Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET\u002FCT Imaging","Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET\u002FCT Imaging)","* INCLUSION CRITERIA\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Participant \\>=18 years old\n4. Has a specific diagnosis of a cardiopulmonary and\u002For vascular disease that puts them at risk of developing or having developed tissue fibrosis.\n5. Has undergone prior imaging of lungs, heart, and\u002For vasculature with chest CT\n6. Able to lie on the PET\u002FCT scanner for imaging up to 45 minutes.\n7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of FAPI-PET\u002FCT or the FDG PET\u002FCT scan.\n8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of FAPI-PET\u002FCT or the FDG PET\u002FCT scan.\n9. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FAPI-74 or other agents used in the study.\n2. Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements\n3. Pregnancy or lactation\n4. Women able to become pregnant or men actively trying to father a child and are unwilling to use an effective form of birth control during the study and 4 weeks after the last 18F-FAPI-74 PET\u002FCT scan or the FDG PET\u002FCT scan.\n5. Subjects with severe claustrophobia unresponsive to oral anxiolytics.\n6. Subjects weighing \\> 350 lbs (weight limit for PET scanner table), or unable to fit within the imaging gantry","ALL","18 Years","100 Years",{"count":93,"type":94},210,"ESTIMATED","INTERVENTIONAL",[97],"PHASE3","Background:\n\nInjury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help.\n\nObjective:\n\nTo test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease.\n\nEligibility:\n\nPeople aged 18 years and older with lung or heart disease that may cause scarring in those organs.\n\nDesign:\n\nParticipants will have 6 clinic visits over 2 years.\n\nParticipants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart.\n\nThe study tracer will be used with positron emission tomography (PET)\u002Fcomputed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine.\n\nParticipants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits.\n\nParticipants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated....",[100,101,102,103,104,105],"Allogeneic Stem Cell Transplantation","Lung Allograft Transplantation","Interstitial Lung Disease","Acute Lung Injury","Pulmonary Arterial Hypertension","Cardiovascular Diseases",[107,108],"Fibroblast activation protein (FAP) FAPI\u002FPET","Fibrotic Disease Activity","NOT_YET_RECRUITING","2026-07-10",{"date":112,"type":113},"2026-07-13","ACTUAL",{"date":115,"type":94},"2026-07-16",{"date":117,"type":94},"2033-05-26",{"name":50,"class":6},1]